含丹参中药联合GnRH激动剂用于子宫内膜异位症术后治疗的系统评价与Meta分析
本研究系统检索8个数据库至2021年10月,纳入10项随机对照试验共836例患者,比较含丹参中药联合GnRH激动剂与单用GnRH激动剂用于子宫内膜异位症术后治疗的效果。结果显示联合组可显著降低复发风险、提高妊娠率、降低CA-125水平并减少不良反应。
要点
- 含丹参中药联合GnRH激动剂可降低子宫内膜异位症术后复发风险(RR=0.26)。
- 联合治疗可提高妊娠率(RR=1.96)并降低血清CA-125水平(SMD=-0.79)。
- 联合组不良反应显著减少,提示含丹参中药可作为术后治疗选择。
核心结论
- 含丹参中药联合GnRH激动剂可能作为子宫内膜异位症术后治疗的选择,具有提高妊娠率、降低复发和不良反应的潜力。
研究设计与样本
- 系统评价与Meta分析,检索8个数据库至2021年10月,纳入10项比较含丹参中药联合GnRH激动剂与单用GnRH激动剂用于术后子宫内膜异位症管理的随机对照试验,共836例患者。
主要发现
- 与对照组相比,联合组降低子宫内膜异位症复发(RR=0.26;95%CI:0.16-0.41)。
- 联合组提高妊娠率(RR=1.96;95%CI:1.58-2.44)。
- 联合组降低CA-125血清水平(SMD=-0.79;95%CI:-1.11至-0.47)。
- 联合组不良反应显著减少。
临床怎么用
- 对于子宫内膜异位症术后患者,可考虑在GnRH激动剂基础上联合含丹参中药以降低复发、提高妊娠率并减少不良反应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Endometriosis is an estrogen-dependent gynecological inflammatory condition that may lead to infertility and recurrent pelvic pain. The purpose of this research was to determine the efficacy and safety of Salvia miltiorrhiza-containing Chinese herbal medicine (CHM) combined with gonadotropin-releasing hormone agonist (GnRH-a) for postoperative endometriosis management. Methods:Eight databases were systematically searched before October 2021, including PubMed, Embase, Cochrane Library, Scopus, Web of Sceince, CNKI, VIP, and Wanfang. Finally, all randomized controlled studies comparing Salvia miltiorrhiza-containing CHM paired with GnRH-a to GnRH-a alone for postoperative endometriosis management were included. Results: A total of 10 trials involving 836 patients were reported and analyzed. Compared with the control group, the Salvia miltiorrhiza-containing CHM combined with GnRH-a group showed significant superiority in decreasing endometriosis recurrence (risk ratio [RR] = 0.26; 95% confidence intervals [CI]: 0.16-0.41) and increasing the pregnancy rate ([RR] = 1.96; 95% CI: 1.58-2.44). Similarly, the effect of the Salvia miltiorrhiza-containing CHM combined with GnRH-a on CA-125 serum levels was positive (standardized mean difference [SMD] = -0.79; 95% CI: -1.11 to -0.47). Furthermore, this group showed a significant reduction in adverse effects. Conclusion: The results indicate that Salvia miltiorrhiza-containing CHM may be a viable choice for postoperative endometriosis therapy, with the potential to enhance pregnancy while decreasing recurrence and adverse effects.
引用
- Gao Q, Shen L, Jiang B, et al. Salvia miltiorrhiza-Containing Chinese Herbal Medicine Combined With GnRH Agonist for Postoperative Treatment of Endometriosis: A Systematic Review and meta-Analysis. Front Pharmacol. 2022. PMID: 35250579. doi:10.3389/fphar.2022.831850
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。